Citations

Clear

2429 citation(s) found for "Shah, SS".

Clinical utility of ECAP dosing in a real-world population delivered via EVOKE therapy: the ECAP study
Pope, Jill , Smith, Gregory L. , Goree, Johnathan , Mekhail, Nagy , Levy, Robert M. , Deer, Timothy R. , Vu, Chau , Shah, Jarna R , Costandi, Shrif , Rosen, Steven M., Bromberg, Todd A., Patel, Atish, Latif, Usman , Lad, Shivanand P. , Jameson, Jessica , Calodney, Aaron , Falowski, Steven , Smith, J. Carson , Guirguis, Maged , Boeding, Ronald B., Sprintz, Michael, Antony, Ajay, Patterson, Denis G., Laufer, Andras, Pilitsis, Julie G. , Miller, Nathan , Rosenfeld, David J. , Tate, Jordan L, Raslan, Ahmed M. , Kallewaard, Jan Willem , Leitner, Angela , Hanson, Erin, Soliday, Nicole, Petersen, Erika , Goree, Johnathan A , Mekhail, Nagy A , Costandi, Shrif J , Lam, Christopher M , Hayek, Salim , Hagedorn, Jonathan M , Kallewaard, Jan Willem , Duarte, Rui , Deer, Tim , Shah, Jarna , Rosen, Steven M, Sayed, Dawood , Lam, Christopher , Hayek, Salim M. , Hagedorn, Jonathan M. , Heros, Robert , Miller, Nathan, Tate, Jordan L, Hanson, Erin, Duarte, Rui

Mayo Clinic

Regional Anesthesia & Pain Medicine | December 2, 2025 | Volume: No volume available | Issue: No issue available | Pages: rapm-2025-107051

10.1136/rapm-2025-107051 | PMID 41330601 Get It

Background The efficacy of EVOKE therapy, a closed-loop spinal cord stimulation (SCS) system, has been demonstrated in a double-blinded randomized controlled trial (RCT). RCT evidence, however, may not be generalizable to clinical practice, while limitations of real-world evidence may affect its validity. The aim of this study was to evaluate the effectiveness of EVOKE therapy in routine clinical practice employing a rigorous data collection approach. Methods The ECAP study was a prospective, multicenter, single-arm, pragmatic study that enrolled SCS candidates with chronic, intractable trunk and/or limb pain in 22 US investigational sites. PROMIS-29 questionnaire and objective neurophysiological metrics were collected, and minimal clinically important differences (MCIDs) were used to characterize baseline dysfunction and response to EVOKE therapy both at trial end and maximal analgesic effect post-implant visit. Pre-specified subgroup analyses were conducted based on diagnosis. Results EVOKE therapy observed included a dose ratio of 1.3 and neural dose accuracy of 2.8 μV. Improvements of >1 MCID were observed for all domains and improvements of ≥2 MCIDs were observed for six of the seven domains. Improvements observed at trial end were maintained or improved at post-implant visit, with statistically significant improvement in holistic MCID (MD 0.2, 95% CI 0.1 to 0.4, p=0.004), and a significantly greater proportion of patients considered holistic MCID responders (p=0.047). Subgroup analysis by diagnosis showed similar outcomes. Conclusions EVOKE therapy was associated with clinically meaningful improvements in a real-world chronic pain population across different subgroups and disease pathologies, with effects observed at trial end reproduced at post-implant visit.
Impact of CKD on Angiodysplasia-Related Gastrointestinal Bleeding: Incidence, Outcomes, and Readmission Risk in a National Cohort
He, Mingyue , Shah, Ankur , Wang, Yichen , Gillespie, Avrum

Mayo Clinic

Journal of the American Society of Nephrology | December 1, 2025 | Volume: 36 | Issue: 10S | Pages: No page available

10.1681/asn.2025rhhvc128 Get It

Benefits and risks of hair, skin, and nail supplements in older adults
Shing, Vivian, Sierra, Ana Aragon, Shing, Vivian, Shah, Amit

Mayo Clinic

International Journal of Women’s Dermatology | November 26, 2025 | Volume: 11 | Issue: 4 | Pages: e236

10.1097/jw9.0000000000000236 | PMID 41278416 Get It

Many older adults, particularly older women, use over-the-counter supplements for antiaging benefits, including for hair and skin. The supplement industry is unregulated by the Food and Drug Administration, and the interactions between supplements and medications are often overlooked by both patients and physicians. This article discusses the proposed mechanism of action, common misconceptions, possible benefits, and potential side effects of the most commonly used antiaging skin supplements by women, including biotin, nicotinamide, hyaluronic acid, collagen, zinc, vitamin C, vitamin A, vitamin E, and other antioxidants. Supplements may also interfere with common blood tests, such as biotin with the thyroid and troponin cardiac enzyme tests, which patients and their clinicians must be aware of and account for when interpreting lab results. Other supplements, such as zinc, are commonly taken in excess and may result in deficiencies in the absorption of other minerals, such as copper. Over-supplementation of fat-soluble vitamins, such as vitamin A and vitamin E, can result in toxic levels since excess is not excreted in the urine. The clinician caring for older patients’ skin and nails must ask older patients about supplement use and be aware of the potential harms of these supplements in some patients.
Socioeconomic position and its effect on cardiovascular outcomes and mortality in patients with prostate cancer
Nahle, Tarek , Shah, Viraj , Kunhiraman, Harikrishnan Hyma , Afzal, Muhammad Umar , Riaz, Irbaz Bin , Agarwal, Neeraj , Swami, Umang , Rachoin, Jean-Sébastien , Weintraub, Neal L, Guha, Avirup , Makram, Omar M , Shah, Viraj R , Hyma Kunhiraman, Harikrishnan , Afzal, Muhammad Umar , Riaz, Irbaz B , Agarwal, Archana M , Swami, Umang , Rachoin, Jean-Sebastien , Guha, Avirup

Mayo Clinic

JNCI Cancer Spectrum | November 26, 2025 | Volume: 9 | Issue: 6 | Pages: No page available

10.1093/jncics/pkaf113 | PMID 41308174 Get It

Abstract Background Socioeconomic position (SEP) is a fundamental social determinant of health (SDoH) contributing to observed disparities in cancer and cardiovascular (CV) care among individuals with prostate cancer (PC). Understanding the influence of SEP on CV health is essential for addressing outcome inequities within this population. Methods We conducted a retrospective study utilizing Surveillance, Epidemiology, and End Results (SEER)-Medicare to evaluate CV outcomes in patients ≥65 years with PC from 2009 to 2017. We studied the impact of SEP on cardiovascular events (CVEs), cardiovascular mortality (CVm), PC-specific mortality (PCsm), and all-cause mortality. CVE, CVm, and PCsm were analyzed using competing risk models and all-cause mortality with Cox proportional hazards models. A subgroup analysis was performed in Non-Hispanic Black and Non-Hispanic White individuals. Results We included 141 242 patients of whom 76 844 were in high SEP areas (45.6%) and 64 398 in low SEP ones (54.4%). Both groups had a mean age of 72 years; patients in low SEP areas were 67.5% Non-Hispanic White, 34.4% having diabetes, 73.3% hypertension, and 67.7% dyslipidemia versus the high SEP group with 85.6% Non-Hispanic White, 30.4% diabetes, 69.9% hypertension, and 70.7% dyslipidemia. Patients in low SEP areas had higher risks of CVm (subdistribution hazard ratio [sHR] = 1.18, 95% CI = 1.12 to 1.25), PCsm (sHR = 1.12, 95% CI = 1.06 to 1.17), CVE (sHR = 1.07, 95% CI = 1.04 to 1.09), and all-cause mortality (HR 1.16, 95% CI = 1.13 to 1.20). Accentuated results were shown in the Non-Hispanic Black subgroup. Conclusion Adverse SEP plays a significant role in shaping outcomes among older patients with PC, contributing to elevated risks of adverse CV and survival outcomes.
Effects of Semaglutide in Obesity-Related Heart Failure with Preserved Ejection Fraction Across the Age Spectrum: Findings from the STEP-HFpEF Programme
Moroney, Michael , Verma, Subodh, Kitzman, Dalane W, Rönnbäck, Cecilia, Domdey, A. , Rasmussen, Søren, Patel, Shachi, Kosiborod, Mikhail , Pandey, Ambarish , Verma, Subodh , Borlaug, Barry A. , Butler, Javed , Davies, Melanie J. , Kitzman, Dalane W. , Shah, Sanjiv J , Petrie, Mark C. , Chinnakondepalli, Khaja

Mayo Clinic

European Journal of Heart Failure | November 26, 2025 | Volume: 27 | Issue: 11 | Pages: 2537-2543

10.1002/ejhf.70049 | PMID 41290376 Get It

Abstract Background The prevalence of heart failure with preserved ejection fraction (HFpEF) increases with age, and older adults with HFpEF have worse physical function, quality of life, and clinical outcomes. Semaglutide demonstrated efficacy in the treatment of obesity-related HFpEF in the STEP-HFpEF trials. Some have speculated that older patients may have less to gain from incretin therapies (and perhaps more to lose) than younger patients. Aims In this pre-specified pooled subanalysis of the STEP-HFpEF trials, we evaluated the efficacy of semaglutide across the age spectrum. Methods The STEP-HFpEF and STEP-HFpEF DM trials enrolled participants with obesity-related HFpEF and randomized them to semaglutide 2.4 mg once weekly (n = 573) or placebo (n = 572) for 52 weeks. Dual primary outcomes (change in Kansas City Cardiomyopathy Questionnaire clinical summary score [KCCQ-CSS] and change in body weight) and secondary outcome measures (6-minute walk distance [6MWD], C-reactive protein, hierarchical composite endpoint containing all-cause death, heart failure events, changes in KCCQ-CSS and 6MWD) were compared across specific age groups; <55 years, 55–64 years, 65–74 years and ≥75 years. Results Among 1145 randomized participants, 8.8% (N = 101) were <55, 23.3% (N = 267) were aged between 55–64, 42.4% (N = 485) were between 65–74, and 25.5% (N = 292) were 75 years or over. The efficacy of semaglutide on the dual primary endpoints was consistent across the age spectrum, KCCQ-CSS (p-interaction = 0.80), and body weight (p-interaction = 0.41). Similar benefits were observed for the key secondary endpoints, with no treatment effect heterogeneity across age groups. Moreover, the safety of semaglutide was consistent across age groups. Conclusion In patients with HFpEF enrolled across the STEP-HFpEF and STEP-HFpEF DM trials, treatment with semaglutide improved disease-specific symptoms, physical function and reduced body weight across the age spectrum. The safety profile of semaglutide was consistent in older and younger patients.
Introducing a foundational sequence transformer for range adaptive nucleotide decoding (STRAND)
Ayanian, Shant , Osborne, Collin , Xu, Clark , Molnar, Carl, Das, Pravat, Perez, Xoab, Vassilieva, Natalia , Pondenkandath, Vinay, Kanakiya, Bhargav, Venkatesh, Ganesh, Redlon, Matt , Shah, Vijay H. , Callstrom, Matthew R. , Korfiatis, Panos, Ryu, Alexander J. , Blasi, Marc, Callstrom, Matthew, Ryu, Alexander J. , Myasoedova, Elena , Molnar, Carl, Das, Pravat, Levin, May, Blasi, Marc, Lazaridis, Konstantinos N. , Myasoedova, Elena , Xu, Clark

Mayo Clinic

Briefings in Bioinformatics | November 24, 2025 | Volume: 26 | Issue: 6 | Pages: No page available

10.1093/bib/bbaf618 | PMID 41283814 Get It

Abstract The advent of high-throughput sequencing has led to an exponential increase in genomic data, highlighting the need for efficient and accurate models to analyze and interpret this information. In this study, we introduce a novel, exomic foundational model that leverages a combination of the human reference genome and multispecies data to improve variant detection and interpretation. Our model utilizes a short-range transformer architecture and is trained on a large dataset of human exomic sequences derived from the Tapestry study. Through a series of ablation studies and scaling experiments, we demonstrate the effectiveness of our model in predicting next token accuracy and identifying clinically pathogenic variants. We also show that our model outperforms existing models in a range of downstream tasks, including variant effect prediction and disease state identification. In fact, our largest sequence transformer for range adaptive nucleotide decoding variant (1B parameters) surpassed previous benchmarks, demonstrating a mean accuracy of 0.880 [an 8.2% improvement over the original nucleotide transformer (NT) and a 7% improvement over NT-v2]. Furthermore, we construct a unique exomic ClinVar dataset to evaluate the model’s performance on pathogenicity and disease states. Our results highlight the potential of this model to improve our understanding of the human exome and its role in disease. The model and its applications have significant implications for genomics-based diagnosis and personalized medicine, including tailored therapeutic development.
From abstract to article: publication rates of abstracts presented at the Society for Healthcare Epidemiology of America spring conference 2018 and 2021
Rajani, Aayushi J. , Karatela, Shifa , Modha, Lipi, Bhuptani, Hitanshi, Shah, Purav , Shukla, Anand , Amin, Juhi , Gandhi, Devisha, Chitale, Rohit , Durvasula, Ravi, Oring, Justin , Rajani, Aayushi J , Shukla, Abhijeet , Karatela, Shifa , Chitale, Rohit A , Gandhi, Devisha

Mayo Clinic

Infection Control & Hospital Epidemiology | November 21, 2025 | Volume: 47 | Issue: 1 | Pages: 88-90

10.1017/ice.2025.10348 | PMID 41267527 Get It

Abstract The publication rate of abstracts presented at a conference can provide some insight into its academic quality, although it is hardly the sole metric. We evaluated 351 SHEA Spring Conference abstracts; 49.9% were published. Findings demonstrate the strong academic output of SHEA conferences.
Impact of Facial Surgery Scars on Quality-of-Life: Perspectives of East Asian and White Patients
Garg, Stuti P. , Wan, Rou , Shah, Krish V., Adam, Tarifa H. , Kim, John Y., Galiano, Robert D. , Galiano, Robert D , Reddy, Narainsai K. , Shah, Krish V., Ellis, Marco F.

Mayo Clinic

Journal of Craniofacial Surgery | November 20, 2025 | Volume: 37 | Issue: 3/4 | Pages: 522-525

10.1097/scs.0000000000012216 | PMID 41263428 Get It

Background: Inappropriate facial scarring can lead to significant physical and psychosocial morbidity. There is a need to better understand how scar perception varies across ethnic groups, and how it impacts broader quality-of-life domains such as career and sexual well-being. This study evaluates White and Asian patients’ perceptions of facial scars related to symptoms, appearance, psychosocial health, and career/sexual well-being. Methods: Facial surgery patients from 5 providers were recruited to complete the SCAR-Q and Career/Sexual Well-Being (CS) scales through phone or email. Higher scores on both assessments indicate more positive patient perceptions. Results: Among the 147 respondents, 50.3% were Asian and 49.7% were White. Procedures included blepharoplasty (n=56), rhinoplasty (n=20), eyelid revision (n=19), facelift (n=18), Mohs surgery (n=7), chin augmentation (n=6), craniotomy (n=6), and other facial procedures (n=16). White patients scored significantly higher than Asian patients on the SCAR-Q total (median=260 versus 234), appearance (76 versus 59), psychosocial (100 versus 87), and CS (16 versus 12.5) scales ( P =0.004, P <0.001, P =0.026, and P <0.001, respectively). Symptom scores positively correlated with time since surgery in both groups (Asian: r =0.326, P =0.004; White: r =0.319, P =0.011). Conclusions: Asian patients reported more negative perceptions of scar appearance, symptoms, psychosocial impact, and career/sexual well-being than White patients. These findings underscore the importance of tailored follow-up care and counseling to address ethnic differences in scar perception and quality-of-life outcomes.
Exploring the landscape of viral hepatitis: A comprehensive retrospective analysis of mortality trends and disparities in the United States (1999–2020)
Idrees, Usama , Nasir, Safa , Marsool, Mohammad Dheyaa, Saeed, Humza, Fatima, Zainab , Mujeeb, Aafeen , Saeed, Khansha, Shahid, Iqra , Sehar, Ayesha, Imtiaz, Abdullah, Alam, Md Shah , Ahmad, Muhammad Husnain , Marsool, Mohammad Dheyaa Marsool, Saeed, Humza , Saeed, Khansha, Najafi, Syed Muhammad Ali, Ahmed, Ali

Mayo Clinic

Medicine | November 14, 2025 | Volume: 104 | Issue: 46 | Pages: e45793

10.1097/md.0000000000045793 | PMID 41239636 Get It

Viral hepatitis (VH) remains a leading cause of preventable mortality in the United States (US). Despite advancements in antiviral therapies, disparities in VH-related mortality persist across demographic, racial, and geographic groups. This study analyzes trends in VH-related mortality among US adults between 1999 and 2020 to identify high-risk subgroups and inform public health interventions. This retrospective cohort study analyzed VH-related deaths among US adults (≥25 years). Data were obtained from the CDC WONDER database, with cases identified using the International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) codes B15–B19. Age-adjusted mortality rates (AAMRs) were calculated per 1,00,000 individuals and stratified by age, gender, race and geographical location. Temporal trends in mortality were analyzed by estimating annual percentage changes (APCs) in the AAMRs using the joinpoint regression model. A total of 3,59,035 VH-related deaths were recorded among US adults during 1999 to 2020 with a cumulative overall AAMR of 7.36 (95% CI: 7.33–7.38). Overall, the AAMRs increased significantly from 1999 to 2013 (APC: +3.21; P < .01), followed by a significant decline until 2020 (APC: −5.61; P < .01). Men exhibited higher AAMRs than women, with middle-aged adults (45–64 years) most affected compared to young (25–44 years) and older adults (65 to 85+ years). Non-Hispanic (NH) American Indians/Alaska experienced the highest AAMRs followed by NH Blacks/African Americans, Hispanics, NH Asians/Pacific Islanders and NH Whites populations. Geographically, mortality rates were higher in urban areas than in rural areas, in the Western region relative to other regions and in the District of Columbia compared to other states. Significant disparities in VH-related mortality persist across demographic and geographic subgroups, with particularly higher rates among men, NH American Indian/Alaska Native population, middle-aged adults, and residents of urban and Western US regions. Targeted public health strategies are essential to address these inequities and improve outcomes.